Cardio–Renal and Systemic Effects of SGLT2i Dapagliflozin on Short-Term Anthracycline and HER-2-Blocking Agent Therapy-Induced CardiotoxicityVincenzo Quagliariello, Nicola Maurea, Andrea Paccone et al.|Antioxidants|2025Cited by 9
Effect of anti CTLA-4 and PD-1 monoclonal antibodies on systemic SDF-1 and galectin-3 levels through NLRP3 and MyD-88 pathways in preclinical models.Martina Iovine, Nicola Maurea, Vincenzo Quagliariello et al.|Journal of Clinical Oncology|2024Cited by 3
SGLT2i Dapagliflozin decreases NLRP3, IL-1 and PCSK9 expression in preclinical models of short-term doxorubicin cardiotoxicityNicola Maurea, Vincenzo Quagliariello, Maria Laura Canale et al.|European Heart Journal|2023Cited by 3
Effect of sodium-glucose cotransporter 2 inhibitor dapagliflozin on ejection fraction reduction, myocardial and renal NF-κB expression and systemic pro-inflammatory biomarkers in models of short-term doxorubicin cardiotoxicity.Vincenzo Quagliariello, Nicola Maurea, Maria Laura Canale et al.|Journal of Clinical Oncology|2024Cited by 3
SGLT2 i Dapagliflozin reduces NF-kB expression in heart and kydneys of preclinical models exposed to doxorubicin through MYd-88 and NLRP3 pathways: an hystological studyNicola Maurea, Vincenzo Quagliariello, Isabella Bisceglia et al.|European Heart Journal|2023Cited by 2